CA2594730A1 - Methods and products for in vitro genotyping - Google Patents
Methods and products for in vitro genotyping Download PDFInfo
- Publication number
- CA2594730A1 CA2594730A1 CA002594730A CA2594730A CA2594730A1 CA 2594730 A1 CA2594730 A1 CA 2594730A1 CA 002594730 A CA002594730 A CA 002594730A CA 2594730 A CA2594730 A CA 2594730A CA 2594730 A1 CA2594730 A1 CA 2594730A1
- Authority
- CA
- Canada
- Prior art keywords
- seq
- probes
- genotype
- probe
- genetic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 238000000034 method Methods 0.000 title claims abstract description 276
- 238000003205 genotyping method Methods 0.000 title claims abstract description 102
- 238000000338 in vitro Methods 0.000 title claims abstract description 15
- 230000007614 genetic variation Effects 0.000 claims abstract description 371
- 239000000523 sample Substances 0.000 claims description 527
- 238000009396 hybridization Methods 0.000 claims description 121
- 238000000018 DNA microarray Methods 0.000 claims description 115
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 113
- 238000012886 linear function Methods 0.000 claims description 98
- 238000001514 detection method Methods 0.000 claims description 84
- 230000003321 amplification Effects 0.000 claims description 80
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 80
- 239000003814 drug Substances 0.000 claims description 70
- 239000000427 antigen Substances 0.000 claims description 67
- 108091007433 antigens Proteins 0.000 claims description 66
- 102000036639 antigens Human genes 0.000 claims description 66
- 108091034117 Oligonucleotide Proteins 0.000 claims description 65
- 210000004369 blood Anatomy 0.000 claims description 64
- 239000008280 blood Substances 0.000 claims description 64
- 230000006870 function Effects 0.000 claims description 60
- 238000006243 chemical reaction Methods 0.000 claims description 55
- 206010067484 Adverse reaction Diseases 0.000 claims description 52
- 230000006838 adverse reaction Effects 0.000 claims description 52
- 239000002773 nucleotide Substances 0.000 claims description 48
- 125000003729 nucleotide group Chemical group 0.000 claims description 48
- 238000004422 calculation algorithm Methods 0.000 claims description 47
- 238000011282 treatment Methods 0.000 claims description 45
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 claims description 44
- 102000039446 nucleic acids Human genes 0.000 claims description 42
- 108020004707 nucleic acids Proteins 0.000 claims description 42
- 150000007523 nucleic acids Chemical class 0.000 claims description 42
- 210000003743 erythrocyte Anatomy 0.000 claims description 36
- 238000004458 analytical method Methods 0.000 claims description 35
- 239000007787 solid Substances 0.000 claims description 32
- 239000011521 glass Substances 0.000 claims description 30
- 238000000205 computational method Methods 0.000 claims description 27
- 238000002372 labelling Methods 0.000 claims description 25
- 108020005187 Oligonucleotide Probes Proteins 0.000 claims description 24
- 239000002751 oligonucleotide probe Substances 0.000 claims description 24
- 238000011161 development Methods 0.000 claims description 23
- 102000054765 polymorphisms of proteins Human genes 0.000 claims description 23
- 238000006062 fragmentation reaction Methods 0.000 claims description 21
- 238000012360 testing method Methods 0.000 claims description 21
- 238000013467 fragmentation Methods 0.000 claims description 20
- 239000013642 negative control Substances 0.000 claims description 15
- 238000012549 training Methods 0.000 claims description 14
- 238000004590 computer program Methods 0.000 claims description 11
- 206010061818 Disease progression Diseases 0.000 claims description 10
- 230000005750 disease progression Effects 0.000 claims description 10
- 238000012408 PCR amplification Methods 0.000 claims description 9
- 239000002299 complementary DNA Substances 0.000 claims description 9
- 238000003752 polymerase chain reaction Methods 0.000 claims description 8
- 239000012472 biological sample Substances 0.000 claims description 7
- 230000001225 therapeutic effect Effects 0.000 claims description 7
- 238000011477 surgical intervention Methods 0.000 claims description 6
- 238000009827 uniform distribution Methods 0.000 claims description 5
- 108020004711 Nucleic Acid Probes Proteins 0.000 claims description 4
- 238000013459 approach Methods 0.000 claims description 4
- 239000007850 fluorescent dye Substances 0.000 claims description 4
- 239000002853 nucleic acid probe Substances 0.000 claims description 4
- 238000009007 Diagnostic Kit Methods 0.000 claims description 3
- 238000003556 assay Methods 0.000 claims description 3
- 101000580024 Homo sapiens Blood group Rh(D) polypeptide Proteins 0.000 description 106
- 108090000623 proteins and genes Proteins 0.000 description 98
- 102100027544 Blood group Rh(D) polypeptide Human genes 0.000 description 96
- 108020004414 DNA Proteins 0.000 description 76
- 108700028369 Alleles Proteins 0.000 description 72
- 108010001237 Cytochrome P-450 CYP2D6 Proteins 0.000 description 60
- 102100021704 Cytochrome P450 2D6 Human genes 0.000 description 60
- 239000013615 primer Substances 0.000 description 47
- 201000010099 disease Diseases 0.000 description 40
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 40
- 102100035833 Histo-blood group ABO system transferase Human genes 0.000 description 38
- 229940079593 drug Drugs 0.000 description 37
- 102100038110 Arylamine N-acetyltransferase 2 Human genes 0.000 description 31
- 101000884399 Homo sapiens Arylamine N-acetyltransferase 2 Proteins 0.000 description 31
- 230000002068 genetic effect Effects 0.000 description 31
- 108010081668 Cytochrome P-450 CYP3A Proteins 0.000 description 27
- 102100029363 Cytochrome P450 2C19 Human genes 0.000 description 26
- 101710142428 Cytochrome P450 2C19 Proteins 0.000 description 26
- 230000035772 mutation Effects 0.000 description 25
- 239000012634 fragment Substances 0.000 description 24
- 102100039208 Cytochrome P450 3A5 Human genes 0.000 description 21
- 230000000295 complement effect Effects 0.000 description 21
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 20
- 101000666610 Homo sapiens Blood group Rh(CE) polypeptide Proteins 0.000 description 20
- 108010015167 Low Density Lipoprotein Receptor-Related Protein-5 Proteins 0.000 description 20
- 102100029358 Cytochrome P450 2C9 Human genes 0.000 description 18
- 101710101953 Cytochrome P450 2C9 Proteins 0.000 description 18
- 101001071776 Homo sapiens Glycophorin-B Proteins 0.000 description 18
- 210000004027 cell Anatomy 0.000 description 18
- 101001074244 Homo sapiens Glycophorin-A Proteins 0.000 description 17
- 102100029424 Nucleotide-binding oligomerization domain-containing protein 1 Human genes 0.000 description 17
- 108090000958 Thiopurine S-methyltransferases Proteins 0.000 description 17
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 17
- 102100035716 Glycophorin-A Human genes 0.000 description 16
- 101000833785 Homo sapiens Glycophorin-E Proteins 0.000 description 16
- 102000004377 Thiopurine S-methyltransferases Human genes 0.000 description 16
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 16
- 238000003745 diagnosis Methods 0.000 description 16
- 208000011231 Crohn disease Diseases 0.000 description 15
- 102100026533 Cytochrome P450 1A2 Human genes 0.000 description 15
- 108090000174 Interleukin-10 Proteins 0.000 description 15
- 102000001770 Low Density Lipoprotein Receptor-Related Protein-5 Human genes 0.000 description 15
- 230000014509 gene expression Effects 0.000 description 15
- 102100029359 Cytochrome P450 2C8 Human genes 0.000 description 14
- 101710101951 Cytochrome P450 2C8 Proteins 0.000 description 14
- 102000003814 Interleukin-10 Human genes 0.000 description 14
- 238000012217 deletion Methods 0.000 description 14
- 230000037430 deletion Effects 0.000 description 14
- 229940076144 interleukin-10 Drugs 0.000 description 14
- 102100038341 Blood group Rh(CE) polypeptide Human genes 0.000 description 13
- 206010009900 Colitis ulcerative Diseases 0.000 description 13
- 108010074922 Cytochrome P-450 CYP1A2 Proteins 0.000 description 13
- 108700002046 Nod1 Signaling Adaptor Proteins 0.000 description 13
- 101150005821 Nod1 gene Proteins 0.000 description 13
- 201000006704 Ulcerative Colitis Diseases 0.000 description 13
- 230000008859 change Effects 0.000 description 13
- 108090001067 Angiotensinogen Proteins 0.000 description 12
- 239000003155 DNA primer Substances 0.000 description 12
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 12
- 108010087870 Mannose-Binding Lectin Proteins 0.000 description 12
- 102000004881 Angiotensinogen Human genes 0.000 description 11
- 102100026553 Mannose-binding protein C Human genes 0.000 description 11
- 206010037660 Pyrexia Diseases 0.000 description 11
- 235000018102 proteins Nutrition 0.000 description 11
- 102000004169 proteins and genes Human genes 0.000 description 11
- 102000004190 Enzymes Human genes 0.000 description 10
- 108090000790 Enzymes Proteins 0.000 description 10
- 108090000978 Interleukin-4 Proteins 0.000 description 10
- 108050005144 Multidrug resistance proteins Proteins 0.000 description 10
- 108010060804 Toll-Like Receptor 4 Proteins 0.000 description 10
- 108010014499 beta-2 Adrenergic Receptors Proteins 0.000 description 10
- 229960002685 biotin Drugs 0.000 description 10
- 235000020958 biotin Nutrition 0.000 description 10
- 239000011616 biotin Substances 0.000 description 10
- 238000007639 printing Methods 0.000 description 10
- 238000004393 prognosis Methods 0.000 description 10
- 108020003175 receptors Proteins 0.000 description 10
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 9
- 108010053652 Butyrylcholinesterase Proteins 0.000 description 9
- 102100032404 Cholinesterase Human genes 0.000 description 9
- 102000004388 Interleukin-4 Human genes 0.000 description 9
- 108010057466 NF-kappa B Proteins 0.000 description 9
- 108091028043 Nucleic acid sequence Proteins 0.000 description 9
- 102100039360 Toll-like receptor 4 Human genes 0.000 description 9
- 238000003491 array Methods 0.000 description 9
- 238000007796 conventional method Methods 0.000 description 9
- 229940028885 interleukin-4 Drugs 0.000 description 9
- 238000007403 mPCR Methods 0.000 description 9
- 238000004519 manufacturing process Methods 0.000 description 9
- 239000010445 mica Substances 0.000 description 9
- 229910052618 mica group Inorganic materials 0.000 description 9
- 102000005962 receptors Human genes 0.000 description 9
- 230000004044 response Effects 0.000 description 9
- 230000035945 sensitivity Effects 0.000 description 9
- 238000002560 therapeutic procedure Methods 0.000 description 9
- 102000005720 Glutathione transferase Human genes 0.000 description 8
- 108010070675 Glutathione transferase Proteins 0.000 description 8
- 102000003886 Glycoproteins Human genes 0.000 description 8
- 108090000288 Glycoproteins Proteins 0.000 description 8
- 230000027455 binding Effects 0.000 description 8
- 238000013461 design Methods 0.000 description 8
- 239000013641 positive control Substances 0.000 description 8
- 230000008569 process Effects 0.000 description 8
- 230000000405 serological effect Effects 0.000 description 8
- 102100029470 Apolipoprotein E Human genes 0.000 description 7
- 101710095339 Apolipoprotein E Proteins 0.000 description 7
- 108020002908 Epoxide hydrolase Proteins 0.000 description 7
- 102000014842 Multidrug resistance proteins Human genes 0.000 description 7
- 102000003945 NF-kappa B Human genes 0.000 description 7
- 102000004357 Transferases Human genes 0.000 description 7
- 108090000992 Transferases Proteins 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 230000002949 hemolytic effect Effects 0.000 description 7
- 208000001234 inflammatory bowel disease 5 Diseases 0.000 description 7
- 102220221967 rs765077104 Human genes 0.000 description 7
- 230000009870 specific binding Effects 0.000 description 7
- 102100036321 5-hydroxytryptamine receptor 2A Human genes 0.000 description 6
- 102100034033 Alpha-adducin Human genes 0.000 description 6
- 101710155857 C-C motif chemokine 2 Proteins 0.000 description 6
- 102100024974 Caspase recruitment domain-containing protein 8 Human genes 0.000 description 6
- 108020004705 Codon Proteins 0.000 description 6
- 102100039205 Cytochrome P450 3A4 Human genes 0.000 description 6
- 102000004073 Dopamine D3 Receptors Human genes 0.000 description 6
- 108090000525 Dopamine D3 Receptors Proteins 0.000 description 6
- 101000799076 Homo sapiens Alpha-adducin Proteins 0.000 description 6
- 101000761247 Homo sapiens Caspase recruitment domain-containing protein 8 Proteins 0.000 description 6
- 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 description 6
- 108090000171 Interleukin-18 Proteins 0.000 description 6
- 108010047230 Member 1 Subfamily B ATP Binding Cassette Transporter Proteins 0.000 description 6
- 108091006764 Organic cation transporters Proteins 0.000 description 6
- 108010077971 Plasminogen Inactivators Proteins 0.000 description 6
- 108010011005 STAT6 Transcription Factor Proteins 0.000 description 6
- 108010012996 Serotonin Plasma Membrane Transport Proteins Proteins 0.000 description 6
- 102000019208 Serotonin Plasma Membrane Transport Proteins Human genes 0.000 description 6
- 102100036928 Solute carrier family 22 member 4 Human genes 0.000 description 6
- 102100036924 Solute carrier family 22 member 5 Human genes 0.000 description 6
- 108010090804 Streptavidin Proteins 0.000 description 6
- 230000002411 adverse Effects 0.000 description 6
- 235000001014 amino acid Nutrition 0.000 description 6
- 229940024606 amino acid Drugs 0.000 description 6
- 150000001413 amino acids Chemical class 0.000 description 6
- 108010014494 beta-1 Adrenergic Receptors Proteins 0.000 description 6
- 102000016966 beta-2 Adrenergic Receptors Human genes 0.000 description 6
- 239000000872 buffer Substances 0.000 description 6
- 210000003754 fetus Anatomy 0.000 description 6
- 238000010438 heat treatment Methods 0.000 description 6
- 238000003780 insertion Methods 0.000 description 6
- 230000037431 insertion Effects 0.000 description 6
- 239000012528 membrane Substances 0.000 description 6
- 238000002493 microarray Methods 0.000 description 6
- 102000040430 polynucleotide Human genes 0.000 description 6
- 108091033319 polynucleotide Proteins 0.000 description 6
- 239000002157 polynucleotide Substances 0.000 description 6
- 102220041712 rs200435277 Human genes 0.000 description 6
- 108010045815 superoxide dismutase 2 Proteins 0.000 description 6
- 102100033350 ATP-dependent translocase ABCB1 Human genes 0.000 description 5
- 102000000018 Chemokine CCL2 Human genes 0.000 description 5
- 102000002004 Cytochrome P-450 Enzyme System Human genes 0.000 description 5
- 108010015742 Cytochrome P-450 Enzyme System Proteins 0.000 description 5
- 102000005486 Epoxide hydrolase Human genes 0.000 description 5
- 108700024394 Exon Proteins 0.000 description 5
- 102100037877 Intercellular adhesion molecule 1 Human genes 0.000 description 5
- 101800003050 Interleukin-16 Proteins 0.000 description 5
- 102000003810 Interleukin-18 Human genes 0.000 description 5
- 102100029193 Low affinity immunoglobulin gamma Fc region receptor III-A Human genes 0.000 description 5
- HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 description 5
- 125000003047 N-acetyl group Chemical group 0.000 description 5
- 102100034559 Natural resistance-associated macrophage protein 1 Human genes 0.000 description 5
- 102000010752 Plasminogen Inactivators Human genes 0.000 description 5
- 108091006619 SLC11A1 Proteins 0.000 description 5
- 102000013968 STAT6 Transcription Factor Human genes 0.000 description 5
- 102100032891 Superoxide dismutase [Mn], mitochondrial Human genes 0.000 description 5
- 102000016967 beta-1 Adrenergic Receptors Human genes 0.000 description 5
- 239000003246 corticosteroid Substances 0.000 description 5
- 238000002405 diagnostic procedure Methods 0.000 description 5
- 230000003993 interaction Effects 0.000 description 5
- 230000008018 melting Effects 0.000 description 5
- 238000002844 melting Methods 0.000 description 5
- 239000002797 plasminogen activator inhibitor Substances 0.000 description 5
- 238000012545 processing Methods 0.000 description 5
- 102220211297 rs1060499711 Human genes 0.000 description 5
- 102220281587 rs1555515276 Human genes 0.000 description 5
- 102200094900 rs1799930 Human genes 0.000 description 5
- 102200094879 rs1801279 Human genes 0.000 description 5
- 102200085943 rs6190 Human genes 0.000 description 5
- 102000049773 5-HT2A Serotonin Receptor Human genes 0.000 description 4
- 108010072564 5-HT2A Serotonin Receptor Proteins 0.000 description 4
- 101100284398 Bos taurus BoLA-DQB gene Proteins 0.000 description 4
- 102000008756 Bradykinin receptor B2 Human genes 0.000 description 4
- 108050000671 Bradykinin receptor B2 Proteins 0.000 description 4
- 108090000566 Caspase-9 Proteins 0.000 description 4
- 102000006378 Catechol O-methyltransferase Human genes 0.000 description 4
- 108020002739 Catechol O-methyltransferase Proteins 0.000 description 4
- 108010008286 DNA nucleotidylexotransferase Proteins 0.000 description 4
- 102100029764 DNA-directed DNA/RNA polymerase mu Human genes 0.000 description 4
- 102000016911 Deoxyribonucleases Human genes 0.000 description 4
- 108010053770 Deoxyribonucleases Proteins 0.000 description 4
- 108010007005 Estrogen Receptor alpha Proteins 0.000 description 4
- 108010027992 HSP70 Heat-Shock Proteins Proteins 0.000 description 4
- 101001076407 Homo sapiens Interleukin-1 receptor antagonist protein Proteins 0.000 description 4
- 101001125032 Homo sapiens Nucleotide-binding oligomerization domain-containing protein 1 Proteins 0.000 description 4
- 206010061218 Inflammation Diseases 0.000 description 4
- 102000049772 Interleukin-16 Human genes 0.000 description 4
- 102100029684 Methylenetetrahydrofolate reductase Human genes 0.000 description 4
- 108010016731 PPAR gamma Proteins 0.000 description 4
- 108010001511 Pregnane X Receptor Proteins 0.000 description 4
- 108010060818 Toll-Like Receptor 9 Proteins 0.000 description 4
- 102100033733 Tumor necrosis factor receptor superfamily member 1B Human genes 0.000 description 4
- 101710187830 Tumor necrosis factor receptor superfamily member 1B Proteins 0.000 description 4
- 101150099178 abo gene Proteins 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 102220396502 c.796C>A Human genes 0.000 description 4
- 238000004132 cross linking Methods 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 102000054766 genetic haplotypes Human genes 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- 230000004054 inflammatory process Effects 0.000 description 4
- 239000003112 inhibitor Substances 0.000 description 4
- 239000003550 marker Substances 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 238000011002 quantification Methods 0.000 description 4
- 230000005855 radiation Effects 0.000 description 4
- 230000002285 radioactive effect Effects 0.000 description 4
- 102220283144 rs1219033025 Human genes 0.000 description 4
- 102200094927 rs1799931 Human genes 0.000 description 4
- 102200010908 rs386833631 Human genes 0.000 description 4
- 102220285330 rs61751644 Human genes 0.000 description 4
- 102220059233 rs63750817 Human genes 0.000 description 4
- -1 s Species 0.000 description 4
- 238000012163 sequencing technique Methods 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 238000010200 validation analysis Methods 0.000 description 4
- 102000009310 vitamin D receptors Human genes 0.000 description 4
- 108050000156 vitamin D receptors Proteins 0.000 description 4
- 101710188260 5,10-methylenetetrahydrofolate reductase Proteins 0.000 description 3
- 102100020895 Ammonium transporter Rh type A Human genes 0.000 description 3
- 102100039705 Beta-2 adrenergic receptor Human genes 0.000 description 3
- 102000004039 Caspase-9 Human genes 0.000 description 3
- 102100027834 DNA repair protein XRCC1 Human genes 0.000 description 3
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 3
- 102100036534 Glutathione S-transferase Mu 1 Human genes 0.000 description 3
- 102100030943 Glutathione S-transferase P Human genes 0.000 description 3
- 108010053864 HLA-DQ4 antigen Proteins 0.000 description 3
- 102000018932 HSP70 Heat-Shock Proteins Human genes 0.000 description 3
- 101001075525 Homo sapiens Ammonium transporter Rh type A Proteins 0.000 description 3
- 101000678879 Homo sapiens Atypical chemokine receptor 1 Proteins 0.000 description 3
- 101100334515 Homo sapiens FCGR3A gene Proteins 0.000 description 3
- 101001010139 Homo sapiens Glutathione S-transferase P Proteins 0.000 description 3
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 description 3
- 101000587058 Homo sapiens Methylenetetrahydrofolate reductase Proteins 0.000 description 3
- 101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 description 3
- 101000998184 Homo sapiens NF-kappa-B inhibitor-like protein 1 Proteins 0.000 description 3
- 101000713272 Homo sapiens Solute carrier family 22 member 4 Proteins 0.000 description 3
- 229940119178 Interleukin 1 receptor antagonist Drugs 0.000 description 3
- 108090000193 Interleukin-1 beta Proteins 0.000 description 3
- 102000051628 Interleukin-1 receptor antagonist Human genes 0.000 description 3
- 108091092195 Intron Proteins 0.000 description 3
- 125000000769 L-threonyl group Chemical group [H]N([H])[C@]([H])(C(=O)[*])[C@](O[H])(C([H])([H])[H])[H] 0.000 description 3
- 102220582371 Mannose-binding protein C_T24A_mutation Human genes 0.000 description 3
- 102100033102 NF-kappa-B inhibitor-like protein 1 Human genes 0.000 description 3
- 102100038494 Nuclear receptor subfamily 1 group I member 2 Human genes 0.000 description 3
- 239000004677 Nylon Substances 0.000 description 3
- 102220558424 Olfactory receptor 9G4_V222A_mutation Human genes 0.000 description 3
- 102000004316 Oxidoreductases Human genes 0.000 description 3
- 108090000854 Oxidoreductases Proteins 0.000 description 3
- 102100038825 Peroxisome proliferator-activated receptor gamma Human genes 0.000 description 3
- 108091006584 SLC14A1 Proteins 0.000 description 3
- 108091006737 SLC22A4 Proteins 0.000 description 3
- 108091006736 SLC22A5 Proteins 0.000 description 3
- 108010038615 Solute Carrier Family 22 Member 5 Proteins 0.000 description 3
- 102220520724 Toll-like receptor 1_R80T_mutation Human genes 0.000 description 3
- 102100033117 Toll-like receptor 9 Human genes 0.000 description 3
- 239000011543 agarose gel Substances 0.000 description 3
- 230000000692 anti-sense effect Effects 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 102220355093 c.143T>C Human genes 0.000 description 3
- 102220361680 c.14690G>A Human genes 0.000 description 3
- 102220359162 c.265C>T Human genes 0.000 description 3
- 102220422558 c.3198C>G Human genes 0.000 description 3
- 102220384325 c.509T>C Human genes 0.000 description 3
- 102220418783 c.733C>G Human genes 0.000 description 3
- 238000012512 characterization method Methods 0.000 description 3
- 230000008021 deposition Effects 0.000 description 3
- 238000005137 deposition process Methods 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 108010032440 glutathione S-transferase M1 Proteins 0.000 description 3
- 239000003407 interleukin 1 receptor blocking agent Substances 0.000 description 3
- 230000000968 intestinal effect Effects 0.000 description 3
- GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 description 3
- 229920001778 nylon Polymers 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 230000036961 partial effect Effects 0.000 description 3
- 239000004033 plastic Substances 0.000 description 3
- 229920001296 polysiloxane Polymers 0.000 description 3
- 239000002243 precursor Substances 0.000 description 3
- 230000006798 recombination Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 102200117339 rs1053359 Human genes 0.000 description 3
- 102220224645 rs1060500185 Human genes 0.000 description 3
- 102220230053 rs1064793357 Human genes 0.000 description 3
- 102220227444 rs1064796375 Human genes 0.000 description 3
- 102220026974 rs111052004 Human genes 0.000 description 3
- 102200117332 rs121912762 Human genes 0.000 description 3
- 102220325559 rs1275262402 Human genes 0.000 description 3
- 102220272883 rs1309097254 Human genes 0.000 description 3
- 102220297001 rs138150805 Human genes 0.000 description 3
- 102220072765 rs146093871 Human genes 0.000 description 3
- 102220307885 rs1554015395 Human genes 0.000 description 3
- 102220278720 rs1554305000 Human genes 0.000 description 3
- 102200149879 rs1555401676 Human genes 0.000 description 3
- 102220276046 rs1555913494 Human genes 0.000 description 3
- 102200043502 rs1800451 Human genes 0.000 description 3
- 102200015977 rs1801166 Human genes 0.000 description 3
- 102220032858 rs1806201 Human genes 0.000 description 3
- 102220008868 rs193922323 Human genes 0.000 description 3
- 102220025220 rs199476357 Human genes 0.000 description 3
- 102220102680 rs201305783 Human genes 0.000 description 3
- 102220075529 rs201922955 Human genes 0.000 description 3
- 102220417282 rs2234693 Human genes 0.000 description 3
- 102200155809 rs28371686 Human genes 0.000 description 3
- 102220221137 rs370328209 Human genes 0.000 description 3
- 102220028600 rs398123116 Human genes 0.000 description 3
- 102200155641 rs41291556 Human genes 0.000 description 3
- 102220045402 rs41294986 Human genes 0.000 description 3
- 102200098764 rs4986790 Human genes 0.000 description 3
- 102220026861 rs587778967 Human genes 0.000 description 3
- 102200108474 rs587780068 Human genes 0.000 description 3
- 102220041877 rs587780794 Human genes 0.000 description 3
- 102220005625 rs6189 Human genes 0.000 description 3
- 102200027492 rs63750285 Human genes 0.000 description 3
- 102220057154 rs730880857 Human genes 0.000 description 3
- 102220075956 rs745767054 Human genes 0.000 description 3
- 102220323721 rs759563305 Human genes 0.000 description 3
- 102220086965 rs760442763 Human genes 0.000 description 3
- 102220342292 rs767831048 Human genes 0.000 description 3
- 102220270238 rs773240506 Human genes 0.000 description 3
- 102220285547 rs777948908 Human genes 0.000 description 3
- 102220094458 rs779917781 Human genes 0.000 description 3
- 102220059791 rs786203255 Human genes 0.000 description 3
- 102220087465 rs864622369 Human genes 0.000 description 3
- 102220094402 rs876660301 Human genes 0.000 description 3
- 102220096565 rs876660352 Human genes 0.000 description 3
- 102220101199 rs878853854 Human genes 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 238000001356 surgical procedure Methods 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- KZMAWJRXKGLWGS-UHFFFAOYSA-N 2-chloro-n-[4-(4-methoxyphenyl)-1,3-thiazol-2-yl]-n-(3-methoxypropyl)acetamide Chemical compound S1C(N(C(=O)CCl)CCCOC)=NC(C=2C=CC(OC)=CC=2)=C1 KZMAWJRXKGLWGS-UHFFFAOYSA-N 0.000 description 2
- 108020005345 3' Untranslated Regions Proteins 0.000 description 2
- 102220574396 5-hydroxytryptamine receptor 2A_H452Y_mutation Human genes 0.000 description 2
- 108010049290 ADP Ribose Transferases Proteins 0.000 description 2
- 102000009062 ADP Ribose Transferases Human genes 0.000 description 2
- 101150059573 AGTR1 gene Proteins 0.000 description 2
- 102100021954 Alpha-tubulin N-acetyltransferase 1 Human genes 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 108090001004 Aquaporin 1 Proteins 0.000 description 2
- 102100023771 Aquaporin-1 Human genes 0.000 description 2
- 102100022717 Atypical chemokine receptor 1 Human genes 0.000 description 2
- 208000023275 Autoimmune disease Diseases 0.000 description 2
- 108090001008 Avidin Proteins 0.000 description 2
- 102220485270 CAP-Gly domain-containing linker protein 1_C112R_mutation Human genes 0.000 description 2
- 102100025064 Cellular tumor antigen p53 Human genes 0.000 description 2
- 108010003384 Colony-Stimulating Factor Receptors Proteins 0.000 description 2
- 108020004635 Complementary DNA Proteins 0.000 description 2
- 101710104280 Cytochrome P450 1A2 Proteins 0.000 description 2
- 101710142379 Cytochrome P450 2C29 Proteins 0.000 description 2
- 102220595803 Cytochrome P450 2D6_V11M_mutation Human genes 0.000 description 2
- 102000011724 DNA Repair Enzymes Human genes 0.000 description 2
- 108010076525 DNA Repair Enzymes Proteins 0.000 description 2
- 238000007400 DNA extraction Methods 0.000 description 2
- 241000255581 Drosophila <fruit fly, genus> Species 0.000 description 2
- 102100032249 Dystonin Human genes 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 102100038595 Estrogen receptor Human genes 0.000 description 2
- 201000006107 Familial adenomatous polyposis Diseases 0.000 description 2
- 241001123946 Gaga Species 0.000 description 2
- 108090000079 Glucocorticoid Receptors Proteins 0.000 description 2
- 108010043428 Glycine hydroxymethyltransferase Proteins 0.000 description 2
- 102100036430 Glycophorin-B Human genes 0.000 description 2
- 101100118545 Holotrichia diomphalia EGF-like gene Proteins 0.000 description 2
- 101000718243 Homo sapiens Adhesion G protein-coupled receptor E5 Proteins 0.000 description 2
- 101001076418 Homo sapiens Interleukin-1 receptor type 1 Proteins 0.000 description 2
- 101001076422 Homo sapiens Interleukin-1 receptor type 2 Proteins 0.000 description 2
- 101000831567 Homo sapiens Toll-like receptor 2 Proteins 0.000 description 2
- 241000725303 Human immunodeficiency virus Species 0.000 description 2
- 102000003777 Interleukin-1 beta Human genes 0.000 description 2
- 102100026016 Interleukin-1 receptor type 1 Human genes 0.000 description 2
- 108090001005 Interleukin-6 Proteins 0.000 description 2
- 102000006541 Ionotropic Glutamate Receptors Human genes 0.000 description 2
- 108010008812 Ionotropic Glutamate Receptors Proteins 0.000 description 2
- 102100021926 Low-density lipoprotein receptor-related protein 5 Human genes 0.000 description 2
- 108010016160 Matrix Metalloproteinase 3 Proteins 0.000 description 2
- 102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 description 2
- 102100037602 P2X purinoceptor 7 Human genes 0.000 description 2
- 108010080192 Purinergic Receptors Proteins 0.000 description 2
- 101100061202 Rattus norvegicus Cyp2a2 gene Proteins 0.000 description 2
- 102000019394 Serine hydroxymethyltransferases Human genes 0.000 description 2
- 108010060826 Toll-Like Receptor 6 Proteins 0.000 description 2
- 102000002689 Toll-like receptor Human genes 0.000 description 2
- 108020000411 Toll-like receptor Proteins 0.000 description 2
- 108010060889 Toll-like receptor 1 Proteins 0.000 description 2
- 102100024333 Toll-like receptor 2 Human genes 0.000 description 2
- 108050002568 Tumor necrosis factor ligand superfamily member 6 Proteins 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 108010000443 X-ray Repair Cross Complementing Protein 1 Proteins 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 239000003435 antirheumatic agent Substances 0.000 description 2
- 210000003050 axon Anatomy 0.000 description 2
- 102220351500 c.1073T>C Human genes 0.000 description 2
- 102220385530 c.1927G>A Human genes 0.000 description 2
- 102220430024 c.2561T>C Human genes 0.000 description 2
- 102220359125 c.48G>A Human genes 0.000 description 2
- 102220364116 c.517A>G Human genes 0.000 description 2
- 102220356997 c.72T>G Human genes 0.000 description 2
- 102220418949 c.8029G>T Human genes 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 description 2
- 208000029664 classic familial adenomatous polyposis Diseases 0.000 description 2
- 238000004140 cleaning Methods 0.000 description 2
- 206010009887 colitis Diseases 0.000 description 2
- 239000013068 control sample Substances 0.000 description 2
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 231100000517 death Toxicity 0.000 description 2
- 230000007613 environmental effect Effects 0.000 description 2
- 210000003617 erythrocyte membrane Anatomy 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 230000005284 excitation Effects 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 238000012252 genetic analysis Methods 0.000 description 2
- 108091008039 hormone receptors Proteins 0.000 description 2
- 238000011065 in-situ storage Methods 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 229960001428 mercaptopurine Drugs 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 244000045947 parasite Species 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 238000000206 photolithography Methods 0.000 description 2
- 239000011148 porous material Substances 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 230000002250 progressing effect Effects 0.000 description 2
- 238000011321 prophylaxis Methods 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 102200103823 rs104886043 Human genes 0.000 description 2
- 102220259980 rs1060503337 Human genes 0.000 description 2
- 102200001415 rs121908891 Human genes 0.000 description 2
- 102200136804 rs121913624 Human genes 0.000 description 2
- 102200027697 rs1300651770 Human genes 0.000 description 2
- 102220334707 rs1553999038 Human genes 0.000 description 2
- 102220278439 rs1553999477 Human genes 0.000 description 2
- 102220278476 rs1554001953 Human genes 0.000 description 2
- 102220318224 rs1554079972 Human genes 0.000 description 2
- 102220280402 rs1555166664 Human genes 0.000 description 2
- 102220281637 rs1555509771 Human genes 0.000 description 2
- 102220283116 rs1555590925 Human genes 0.000 description 2
- 102220272815 rs1555592618 Human genes 0.000 description 2
- 102220245290 rs1555592634 Human genes 0.000 description 2
- 102200038836 rs199472824 Human genes 0.000 description 2
- 102200004568 rs267607387 Human genes 0.000 description 2
- 102220244982 rs376736188 Human genes 0.000 description 2
- 102220046314 rs587782826 Human genes 0.000 description 2
- 102200164266 rs63750430 Human genes 0.000 description 2
- 102220027181 rs63751707 Human genes 0.000 description 2
- 102220099380 rs753686197 Human genes 0.000 description 2
- 102220277685 rs775776362 Human genes 0.000 description 2
- 102220022232 rs80357198 Human genes 0.000 description 2
- FZHAPNGMFPVSLP-UHFFFAOYSA-N silanamine Chemical class [SiH3]N FZHAPNGMFPVSLP-UHFFFAOYSA-N 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 238000002054 transplantation Methods 0.000 description 2
- 230000032258 transport Effects 0.000 description 2
- RCTYDUUDOSRQTI-WSZWBAFRSA-N (2s)-1-formyl-n-[(2s)-1-oxopropan-2-yl]pyrrolidine-2-carboxamide;propane Chemical compound CCC.O=C[C@H](C)NC(=O)[C@@H]1CCCN1C=O RCTYDUUDOSRQTI-WSZWBAFRSA-N 0.000 description 1
- BCOSEZGCLGPUSL-UHFFFAOYSA-N 2,3,3-trichloroprop-2-enoyl chloride Chemical compound ClC(Cl)=C(Cl)C(Cl)=O BCOSEZGCLGPUSL-UHFFFAOYSA-N 0.000 description 1
- 101710138091 5-hydroxytryptamine receptor 2A Proteins 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 102100026423 Adhesion G protein-coupled receptor E5 Human genes 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 102100030793 Ammonium transporter Rh type B Human genes 0.000 description 1
- 102100038343 Ammonium transporter Rh type C Human genes 0.000 description 1
- 102000005862 Angiotensin II Human genes 0.000 description 1
- 101800000733 Angiotensin-2 Proteins 0.000 description 1
- HZYFHQOWCFUSOV-IMJSIDKUSA-N Asn-Asp Chemical compound NC(=O)C[C@H](N)C(=O)N[C@@H](CC(O)=O)C(O)=O HZYFHQOWCFUSOV-IMJSIDKUSA-N 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 102100040794 Beta-1 adrenergic receptor Human genes 0.000 description 1
- 102220596593 Blood group Rh(CE) polypeptide_Q41R_mutation Human genes 0.000 description 1
- 101800004538 Bradykinin Proteins 0.000 description 1
- 102000010183 Bradykinin receptor Human genes 0.000 description 1
- 108050001736 Bradykinin receptor Proteins 0.000 description 1
- 102100035875 C-C chemokine receptor type 5 Human genes 0.000 description 1
- 101710149870 C-C chemokine receptor type 5 Proteins 0.000 description 1
- 108010040471 CC Chemokines Proteins 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 101710142739 Caspase recruitment domain-containing protein 8 Proteins 0.000 description 1
- 108010076667 Caspases Proteins 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 102000004626 Colony-Stimulating Factor Receptors Human genes 0.000 description 1
- 241000223936 Cryptosporidium parvum Species 0.000 description 1
- 102100031476 Cytochrome P450 1A1 Human genes 0.000 description 1
- 101710104049 Cytochrome P450 1A1 Proteins 0.000 description 1
- 102000018832 Cytochromes Human genes 0.000 description 1
- 108010052832 Cytochromes Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000012410 DNA Ligases Human genes 0.000 description 1
- 108010061982 DNA Ligases Proteins 0.000 description 1
- 101710147739 DNA repair protein XRCC1 Proteins 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 101150034979 DRB3 gene Proteins 0.000 description 1
- 101710088194 Dehydrogenase Proteins 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 229940123907 Disease modifying antirheumatic drug Drugs 0.000 description 1
- 102100022258 Disks large homolog 5 Human genes 0.000 description 1
- 101710083262 Ectin Proteins 0.000 description 1
- 102000002045 Endothelin Human genes 0.000 description 1
- 108050009340 Endothelin Proteins 0.000 description 1
- 108700039887 Essential Genes Proteins 0.000 description 1
- 101150050153 FY gene Proteins 0.000 description 1
- 208000034826 Genetic Predisposition to Disease Diseases 0.000 description 1
- 206010071602 Genetic polymorphism Diseases 0.000 description 1
- 102000018899 Glutamate Receptors Human genes 0.000 description 1
- 108010027915 Glutamate Receptors Proteins 0.000 description 1
- 102100038055 Glutathione S-transferase theta-1 Human genes 0.000 description 1
- 102100040870 Glycine amidinotransferase, mitochondrial Human genes 0.000 description 1
- 102220485469 Glycophorin-A_S20L_mutation Human genes 0.000 description 1
- 102000051366 Glycosyltransferases Human genes 0.000 description 1
- 108700023372 Glycosyltransferases Proteins 0.000 description 1
- QXZGBUJJYSLZLT-UHFFFAOYSA-N H-Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg-OH Natural products NC(N)=NCCCC(N)C(=O)N1CCCC1C(=O)N1C(C(=O)NCC(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CO)C(=O)N2C(CCC2)C(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CCCN=C(N)N)C(O)=O)CCC1 QXZGBUJJYSLZLT-UHFFFAOYSA-N 0.000 description 1
- 241000700721 Hepatitis B virus Species 0.000 description 1
- 208000005176 Hepatitis C Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000703292 Homo sapiens Ammonium transporter Rh type B Proteins 0.000 description 1
- 101000666627 Homo sapiens Ammonium transporter Rh type C Proteins 0.000 description 1
- 101000902114 Homo sapiens Disks large homolog 5 Proteins 0.000 description 1
- 101000805172 Homo sapiens Docking protein 1 Proteins 0.000 description 1
- 101001024566 Homo sapiens Ecto-ADP-ribosyltransferase 4 Proteins 0.000 description 1
- 101001032462 Homo sapiens Glutathione S-transferase theta-1 Proteins 0.000 description 1
- 101000893303 Homo sapiens Glycine amidinotransferase, mitochondrial Proteins 0.000 description 1
- 101000930802 Homo sapiens HLA class II histocompatibility antigen, DQ alpha 1 chain Proteins 0.000 description 1
- 101000968028 Homo sapiens HLA class II histocompatibility antigen, DRB1 beta chain Proteins 0.000 description 1
- 101001056794 Homo sapiens Inosine triphosphate pyrophosphatase Proteins 0.000 description 1
- 101001033249 Homo sapiens Interleukin-1 beta Proteins 0.000 description 1
- 101000868279 Homo sapiens Leukocyte surface antigen CD47 Proteins 0.000 description 1
- 101000618525 Homo sapiens Membrane transport protein XK Proteins 0.000 description 1
- 101001116314 Homo sapiens Methionine synthase reductase Proteins 0.000 description 1
- 101001100327 Homo sapiens RNA-binding protein 45 Proteins 0.000 description 1
- 101000934346 Homo sapiens T-cell surface antigen CD2 Proteins 0.000 description 1
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- CZGUSIXMZVURDU-JZXHSEFVSA-N Ile(5)-angiotensin II Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C([O-])=O)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=[NH2+])NC(=O)[C@@H]([NH3+])CC([O-])=O)C(C)C)C1=CC=C(O)C=C1 CZGUSIXMZVURDU-JZXHSEFVSA-N 0.000 description 1
- 208000026350 Inborn Genetic disease Diseases 0.000 description 1
- 102100025458 Inosine triphosphate pyrophosphatase Human genes 0.000 description 1
- 102100037874 Intercellular adhesion molecule 4 Human genes 0.000 description 1
- 101710148793 Intercellular adhesion molecule 4 Proteins 0.000 description 1
- 102100039065 Interleukin-1 beta Human genes 0.000 description 1
- 102100026017 Interleukin-1 receptor type 2 Human genes 0.000 description 1
- 102000004889 Interleukin-6 Human genes 0.000 description 1
- 206010061245 Internal injury Diseases 0.000 description 1
- UETNIIAIRMUTSM-UHFFFAOYSA-N Jacareubin Natural products CC1(C)OC2=CC3Oc4c(O)c(O)ccc4C(=O)C3C(=C2C=C1)O UETNIIAIRMUTSM-UHFFFAOYSA-N 0.000 description 1
- 102100035792 Kininogen-1 Human genes 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- 102000004856 Lectins Human genes 0.000 description 1
- 108090001090 Lectins Proteins 0.000 description 1
- 102100032913 Leukocyte surface antigen CD47 Human genes 0.000 description 1
- 208000019693 Lung disease Diseases 0.000 description 1
- 108091054437 MHC class I family Proteins 0.000 description 1
- 102000000422 Matrix Metalloproteinase 3 Human genes 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 102100022472 Membrane transport protein XK Human genes 0.000 description 1
- 102100024614 Methionine synthase reductase Human genes 0.000 description 1
- 108010030837 Methylenetetrahydrofolate Reductase (NADPH2) Proteins 0.000 description 1
- MBLBDJOUHNCFQT-UHFFFAOYSA-N N-acetyl-D-galactosamine Natural products CC(=O)NC(C=O)C(O)C(O)C(O)CO MBLBDJOUHNCFQT-UHFFFAOYSA-N 0.000 description 1
- BAWFJGJZGIEFAR-NNYOXOHSSA-O NAD(+) Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 BAWFJGJZGIEFAR-NNYOXOHSSA-O 0.000 description 1
- 101100278514 Oryza sativa subsp. japonica DRB2 gene Proteins 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 241000223960 Plasmodium falciparum Species 0.000 description 1
- 241000223810 Plasmodium vivax Species 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 206010036774 Proctitis Diseases 0.000 description 1
- 102000002727 Protein Tyrosine Phosphatase Human genes 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 239000013614 RNA sample Substances 0.000 description 1
- 102100038823 RNA-binding protein 45 Human genes 0.000 description 1
- 208000001709 Rh deficiency syndrome Diseases 0.000 description 1
- 206010039203 Road traffic accident Diseases 0.000 description 1
- 241000702670 Rotavirus Species 0.000 description 1
- 108091006207 SLC-Transporter Proteins 0.000 description 1
- 108091006318 SLC4A1 Proteins 0.000 description 1
- 101100510076 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) KEL1 gene Proteins 0.000 description 1
- 108091081021 Sense strand Proteins 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- 238000002105 Southern blotting Methods 0.000 description 1
- 102100025237 T-cell surface antigen CD2 Human genes 0.000 description 1
- 108010043173 Toll-Like Receptor 10 Proteins 0.000 description 1
- 102000008229 Toll-like receptor 1 Human genes 0.000 description 1
- 108010060888 Toll-like receptor 2 Proteins 0.000 description 1
- 102100039387 Toll-like receptor 6 Human genes 0.000 description 1
- 208000003441 Transfusion reaction Diseases 0.000 description 1
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 description 1
- 102100031988 Tumor necrosis factor ligand superfamily member 6 Human genes 0.000 description 1
- 102000018594 Tumour necrosis factor Human genes 0.000 description 1
- 108050007852 Tumour necrosis factor Proteins 0.000 description 1
- 108060008724 Tyrosinase Proteins 0.000 description 1
- HSCJRCZFDFQWRP-ABVWGUQPSA-N UDP-alpha-D-galactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1OP(O)(=O)OP(O)(=O)OC[C@@H]1[C@@H](O)[C@@H](O)[C@H](N2C(NC(=O)C=C2)=O)O1 HSCJRCZFDFQWRP-ABVWGUQPSA-N 0.000 description 1
- HSCJRCZFDFQWRP-UHFFFAOYSA-N Uridindiphosphoglukose Natural products OC1C(O)C(O)C(CO)OC1OP(O)(=O)OP(O)(=O)OCC1C(O)C(O)C(N2C(NC(=O)C=C2)=O)O1 HSCJRCZFDFQWRP-UHFFFAOYSA-N 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 101000832077 Xenopus laevis Dapper 1-A Proteins 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 238000011366 aggressive therapy Methods 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 230000000961 alloantigen Effects 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 229950006323 angiotensin ii Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 230000000340 anti-metabolite Effects 0.000 description 1
- 230000003356 anti-rheumatic effect Effects 0.000 description 1
- 229940100197 antimetabolite Drugs 0.000 description 1
- 239000002256 antimetabolite Substances 0.000 description 1
- 108010042865 aquacobalamin reductase Proteins 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 1
- 229960002170 azathioprine Drugs 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 230000002457 bidirectional effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 210000001772 blood platelet Anatomy 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- QXZGBUJJYSLZLT-FDISYFBBSA-N bradykinin Chemical compound NC(=N)NCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)NCC(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CO)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)CCC1 QXZGBUJJYSLZLT-FDISYFBBSA-N 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 102220397064 c.1057G>A Human genes 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000001311 chemical methods and process Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 229960003405 ciprofloxacin Drugs 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- 238000012321 colectomy Methods 0.000 description 1
- 230000000112 colonic effect Effects 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 238000005094 computer simulation Methods 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 102000003675 cytokine receptors Human genes 0.000 description 1
- 108010057085 cytokine receptors Proteins 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 239000005546 dideoxynucleotide Substances 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 208000022602 disease susceptibility Diseases 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000013399 early diagnosis Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 108010052621 fas Receptor Proteins 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 238000001215 fluorescent labelling Methods 0.000 description 1
- 238000005558 fluorometry Methods 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 208000016361 genetic disease Diseases 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 230000002489 hematologic effect Effects 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 125000005842 heteroatom Chemical group 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 230000001969 hypertrophic effect Effects 0.000 description 1
- 230000003100 immobilizing effect Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 229960000598 infliximab Drugs 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000015788 innate immune response Effects 0.000 description 1
- 108010029405 inosine triphosphatase Proteins 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 230000001057 ionotropic effect Effects 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 238000005304 joining Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000002523 lectin Substances 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 238000004020 luminiscence type Methods 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000008774 maternal effect Effects 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 238000007479 molecular analysis Methods 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 210000004897 n-terminal region Anatomy 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 238000009828 non-uniform distribution Methods 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 238000007899 nucleic acid hybridization Methods 0.000 description 1
- QQBDLJCYGRGAKP-FOCLMDBBSA-N olsalazine Chemical compound C1=C(O)C(C(=O)O)=CC(\N=N\C=2C=C(C(O)=CC=2)C(O)=O)=C1 QQBDLJCYGRGAKP-FOCLMDBBSA-N 0.000 description 1
- 229960004110 olsalazine Drugs 0.000 description 1
- 208000014965 pancolitis Diseases 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 230000008775 paternal effect Effects 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 102000007863 pattern recognition receptors Human genes 0.000 description 1
- 108010089193 pattern recognition receptors Proteins 0.000 description 1
- NRNCYVBFPDDJNE-UHFFFAOYSA-N pemoline Chemical compound O1C(N)=NC(=O)C1C1=CC=CC=C1 NRNCYVBFPDDJNE-UHFFFAOYSA-N 0.000 description 1
- 102000013415 peroxidase activity proteins Human genes 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 210000002824 peroxisome Anatomy 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 230000001124 posttranscriptional effect Effects 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 108020000494 protein-tyrosine phosphatase Proteins 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 238000007894 restriction fragment length polymorphism technique Methods 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 102220037583 rs11552531 Human genes 0.000 description 1
- 102200102221 rs121908299 Human genes 0.000 description 1
- 102220271662 rs1378561919 Human genes 0.000 description 1
- 102220088168 rs139496777 Human genes 0.000 description 1
- 102220173821 rs142019309 Human genes 0.000 description 1
- 102220101303 rs143215183 Human genes 0.000 description 1
- 102220011559 rs199740875 Human genes 0.000 description 1
- 102220101890 rs200080353 Human genes 0.000 description 1
- 102220046348 rs200632093 Human genes 0.000 description 1
- 102200015325 rs281865563 Human genes 0.000 description 1
- 102200001000 rs387907265 Human genes 0.000 description 1
- 102220012007 rs397515764 Human genes 0.000 description 1
- 102200125187 rs4961 Human genes 0.000 description 1
- 102220045026 rs587781767 Human genes 0.000 description 1
- 102220027465 rs63750597 Human genes 0.000 description 1
- 102220083944 rs751227032 Human genes 0.000 description 1
- 102220214616 rs774127733 Human genes 0.000 description 1
- 102220096629 rs876660063 Human genes 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000007391 self-medication Methods 0.000 description 1
- 239000004065 semiconductor Substances 0.000 description 1
- 238000009589 serological test Methods 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- NCEXYHBECQHGNR-QZQOTICOSA-N sulfasalazine Chemical compound C1=C(O)C(C(=O)O)=CC(\N=N\C=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-QZQOTICOSA-N 0.000 description 1
- 229960001940 sulfasalazine Drugs 0.000 description 1
- NCEXYHBECQHGNR-UHFFFAOYSA-N sulfasalazine Natural products C1=C(O)C(C(=O)O)=CC(N=NC=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-UHFFFAOYSA-N 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 150000003573 thiols Chemical group 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 102000006030 urea transporter Human genes 0.000 description 1
- 108020003234 urea transporter Proteins 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6881—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for tissue or cell typing, e.g. human leukocyte antigen [HLA] probes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6888—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
- C12Q1/6834—Enzymatic or biochemical coupling of nucleic acids to a solid phase
- C12Q1/6837—Enzymatic or biochemical coupling of nucleic acids to a solid phase using probe arrays or probe chips
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/16—Primer sets for multiplex assays
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
- Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Analytical Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- General Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cell Biology (AREA)
- Pathology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Ophthalmology & Optometry (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ES200500089 | 2005-01-13 | ||
| ESP200500089 | 2005-01-13 | ||
| ESP200502423 | 2005-10-05 | ||
| ES200502423A ES2326708B1 (es) | 2005-10-05 | 2005-10-05 | Metodos y productos para genotipado in vitro. |
| US75819206P | 2006-01-12 | 2006-01-12 | |
| US60/758,192 | 2006-01-12 | ||
| PCT/IB2006/000796 WO2006075254A2 (en) | 2005-01-13 | 2006-01-12 | Methods and products for in vitro genotyping |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2594730A1 true CA2594730A1 (en) | 2006-07-20 |
Family
ID=36677993
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002594730A Abandoned CA2594730A1 (en) | 2005-01-13 | 2006-01-12 | Methods and products for in vitro genotyping |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US7914990B2 (enExample) |
| EP (1) | EP1836322B8 (enExample) |
| JP (1) | JP2008526249A (enExample) |
| AU (1) | AU2006205571B2 (enExample) |
| CA (1) | CA2594730A1 (enExample) |
| MX (1) | MX2007008506A (enExample) |
| WO (1) | WO2006075254A2 (enExample) |
Families Citing this family (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8688385B2 (en) * | 2003-02-20 | 2014-04-01 | Mayo Foundation For Medical Education And Research | Methods for selecting initial doses of psychotropic medications based on a CYP2D6 genotype |
| JP5348840B2 (ja) | 2003-02-20 | 2013-11-20 | メイヨ・ファウンデーション・フォー・メディカル・エデュケーション・アンド・リサーチ | 薬物を選択する方法 |
| US8153363B2 (en) * | 2005-01-13 | 2012-04-10 | Progenika Biopharma S.A. | Methods and products for in vitro genotyping |
| CA2911569C (en) | 2005-11-29 | 2019-11-26 | Children's Hospital Medical Center | Optimization and individualization of medication selection and dosing |
| GB0613844D0 (en) * | 2006-07-12 | 2006-08-23 | Progenika Biopharma Sa | Methods and products for in vitro genotyping |
| WO2008066164A1 (fr) * | 2006-11-30 | 2008-06-05 | Arkray, Inc. | Ensemble d'amorces utilisé dans l'amplification du gène de l'obésité, réactif utilisé dans l'amplification du gène de l'obésité comprenant ledit ensemble d'amorce et son utilisation |
| WO2008066161A1 (en) * | 2006-11-30 | 2008-06-05 | Arkray, Inc. | Primer set for amplification of nat2 gene, reagent for amplification of nat2 gene comprising the same, and use of the same |
| JPWO2008066163A1 (ja) * | 2006-11-30 | 2010-03-11 | アークレイ株式会社 | Ｃｙｐ２ｃ９遺伝子増幅用プライマーセット、それを含むｃｙｐ２ｃ９遺伝子増幅用試薬およびその用途 |
| ITMI20070504A1 (it) | 2007-03-13 | 2008-09-14 | Fond Irccs Ospedale Maggiore | Metodo per la tipizzazione genomica di sistemi eritrocitari, sonde oligonucleotidiche e kit diagnostici relativi |
| JP4410269B2 (ja) * | 2007-03-28 | 2010-02-03 | 株式会社東芝 | Ｎ−アセチルトランスフェラーゼ２（ｎａｔ２）の遺伝子型を検出するための核酸プライマーセット、キット、及び該プライマーセットを用いた検出方法 |
| US20100311052A1 (en) * | 2007-06-29 | 2010-12-09 | Biomonitor A/S | Prognostic method for the determination of the suitability of biopharmaceutical treatment |
| WO2009048027A1 (ja) * | 2007-10-09 | 2009-04-16 | Arkray, Inc. | 免疫関連遺伝子の多型の検出用プローブおよびその用途 |
| CA2721651A1 (en) * | 2008-04-18 | 2009-12-03 | University Of Tennessee Research Foundation | Single nucleotide polymorphisms (snp) and association with resistance to immune tolerance induction |
| WO2009130797A1 (ja) * | 2008-04-22 | 2009-10-29 | 東洋鋼鈑株式会社 | Abo式血液型を判定するためのプローブセット |
| US20110229471A1 (en) | 2008-11-26 | 2011-09-22 | Cedars-Sinai Medical Center | Methods of determining responsiveness to anti-tnf alpha therapy in inflammatory bowel disease |
| US9580752B2 (en) * | 2008-12-24 | 2017-02-28 | Cedars-Sinai Medical Center | Methods of predicting medically refractive ulcerative colitis (MR-UC) requiring colectomy |
| US8835111B2 (en) | 2009-03-12 | 2014-09-16 | Brainco Biopharma S.L. | Genotyping tool for improving the prognostic and clinical management of MS patients |
| WO2011027218A1 (en) * | 2009-09-04 | 2011-03-10 | Progenika Biopharma, S.A. | High throughput detection of genomic copy number variations |
| US9677125B2 (en) * | 2009-10-21 | 2017-06-13 | General Electric Company | Detection of plurality of targets in biological samples |
| US9558320B2 (en) * | 2009-10-26 | 2017-01-31 | Genomas, Inc. | Physiogenomic method for predicting drug metabolism reserve for antidepressants and stimulants |
| WO2011155531A1 (ja) * | 2010-06-08 | 2011-12-15 | 独立行政法人国立がん研究センター | 薬剤性肺障害の発症のリスク予測、該リスク予測のための遺伝子の検出方法及び検出用キット |
| ES2641600T3 (es) | 2010-06-18 | 2017-11-10 | Progenika Biopharma, S.A. | Métodos de determinación de la presencia o la ausencia de segmentos genéticos |
| US8766034B2 (en) | 2010-09-22 | 2014-07-01 | Cedars-Sinai Medical Center | TL1A model of inflammation fibrosis and autoimmunity |
| EP2471949B1 (en) * | 2010-12-31 | 2013-12-25 | Progenika Biopharma, S.A. | Method for the identification by molecular techniques of genetic variants that encode no D antigen (D-) and altered C antigen (C+W) |
| JP2012196209A (ja) * | 2011-03-09 | 2012-10-18 | Arkray Inc | Ｃｙｐ３ａ遺伝子の多型検出用プローブ、多型検出方法、薬効評価方法及び多型検出用試薬キット |
| EP2535424B1 (en) * | 2011-06-16 | 2015-08-05 | Gendiag.exe, S.L. | SNPs associated with thromboemoblic disease |
| US10557170B2 (en) | 2011-06-16 | 2020-02-11 | Gendiag.Exe, S.L. | Thromboembolic disease markers |
| EP2721171A1 (en) * | 2011-06-17 | 2014-04-23 | Progenika Biopharma, S.A. | Discrimination of blood type variants |
| AR088867A1 (es) * | 2011-11-15 | 2014-07-16 | Acgt Intellectual Ltd | Metodo y aparato para detectar variacion(es) del acido nucleico |
| EP2596806A1 (en) | 2011-11-25 | 2013-05-29 | Index Pharmaceuticals AB | Method for prevention of colectomy |
| ES2759782T3 (es) * | 2012-01-18 | 2020-05-12 | Shanghai Blood Centre | Procedimiento de detección por PCR múltiplex para tipos sanguíneos humanos poco comunes y kit |
| JP6028300B2 (ja) * | 2012-08-31 | 2016-11-16 | 東洋鋼鈑株式会社 | Ａｂｏ式血液型を判定するためのプライマーセット及びプローブ |
| US20140274763A1 (en) * | 2013-03-15 | 2014-09-18 | Pathway Genomics Corporation | Method and system to predict response to pain treatments |
| EP3639841B1 (en) | 2013-03-27 | 2023-09-06 | Cedars-Sinai Medical Center | Treating fibrosis by inhibiting tl1a |
| EP3022295A4 (en) | 2013-07-19 | 2017-03-01 | Cedars-Sinai Medical Center | Signature of tl1a (tnfsf15) signaling pathway |
| JP2015128399A (ja) * | 2014-01-09 | 2015-07-16 | 東洋紡株式会社 | Ｃｙｐ３ａ５の検出方法 |
| JP7082945B2 (ja) | 2016-03-17 | 2022-06-09 | シーダーズ―シナイ メディカル センター | Ｒｎａｓｅｔ２により炎症性腸疾患を診断する方法 |
| US11699069B2 (en) * | 2017-07-13 | 2023-07-11 | Helix, Inc. | Predictive assignments that relate to genetic information and leverage machine learning models |
| CA3074682A1 (en) * | 2017-09-07 | 2019-03-14 | Regeneron Pharmaceuticals, Inc. | Solute carrier family 14 member 1 (slc14a1) variants and uses thereof |
| EP3697933A4 (en) | 2017-10-20 | 2021-12-08 | The Governors of the University of Alberta | SINGLE NUCLEOTIDE POLYMORPHISMS AND FEEDING EFFICIENCY IN Cattle |
| JP6995604B2 (ja) * | 2017-12-15 | 2022-01-14 | 東洋鋼鈑株式会社 | 一塩基多型検出用プローブの設計方法及びプローブセット |
| JP7308261B2 (ja) * | 2018-08-30 | 2023-07-13 | ライフ テクノロジーズ コーポレーション | ジェノタイピングｐｃｒアッセイのための機械学習システム |
| JP7706698B2 (ja) * | 2020-02-14 | 2025-07-14 | 東レ株式会社 | バイオチップの製造方法 |
| CN112442532B (zh) * | 2020-08-27 | 2023-09-26 | 深圳市卫生健康发展研究中心 | 同时检测20种葡萄糖-6-磷酸脱氢酶缺乏症的引物组及试剂盒 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1165839A2 (en) * | 1999-03-26 | 2002-01-02 | Whitehead Institute For Biomedical Research | Universal arrays |
| WO2001029268A2 (en) | 1999-10-18 | 2001-04-26 | Curagen Corporation | Method for identifying interacting gene products |
| EP1287162A2 (en) * | 1999-10-21 | 2003-03-05 | Case Western Reserve University | Gene expression profiling of inflammatory bowel disease |
| CA2490766A1 (en) * | 2002-06-28 | 2004-01-08 | Applera Corporation | A system and method for snp genotype clustering |
-
2006
- 2006-01-12 JP JP2007550872A patent/JP2008526249A/ja active Pending
- 2006-01-12 WO PCT/IB2006/000796 patent/WO2006075254A2/en not_active Ceased
- 2006-01-12 US US11/813,646 patent/US7914990B2/en active Active
- 2006-01-12 AU AU2006205571A patent/AU2006205571B2/en not_active Ceased
- 2006-01-12 EP EP06727428.2A patent/EP1836322B8/en active Active
- 2006-01-12 MX MX2007008506A patent/MX2007008506A/es active IP Right Grant
- 2006-01-12 CA CA002594730A patent/CA2594730A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US7914990B2 (en) | 2011-03-29 |
| WO2006075254A3 (en) | 2007-03-22 |
| JP2008526249A (ja) | 2008-07-24 |
| MX2007008506A (es) | 2010-05-17 |
| EP1836322B8 (en) | 2017-01-11 |
| AU2006205571A1 (en) | 2006-07-20 |
| EP1836322A2 (en) | 2007-09-26 |
| US20080070253A1 (en) | 2008-03-20 |
| EP1836322B1 (en) | 2016-09-07 |
| WO2006075254A2 (en) | 2006-07-20 |
| AU2006205571B2 (en) | 2012-03-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2006205571B2 (en) | Methods and products for in vitro genotyping | |
| US8153363B2 (en) | Methods and products for in vitro genotyping | |
| US20210222245A1 (en) | Autism associated genetic markers | |
| EP4381099A1 (en) | Methods for detecting neoplasm in pregnant women | |
| EP2061910B1 (en) | Prognostic method | |
| AU2007274720B2 (en) | Method for prognosing osteoporosis phenotypes | |
| EP2471949B1 (en) | Method for the identification by molecular techniques of genetic variants that encode no D antigen (D-) and altered C antigen (C+W) | |
| US20060234221A1 (en) | Biallelic markers of d-amino acid oxidase and uses thereof | |
| US20070048751A1 (en) | Method of diagnosing type II diabetes mellitus using multilocus marker, polynucleotide including marker associated with type II diabetes mellitus, and microarray and diagnostic kit including the polynucleotide | |
| US20140037549A1 (en) | Genetic markers for prognosis of rheumatoid arthritis treatment efficacy |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| FZDE | Discontinued |
Effective date: 20170330 |